Epidermolysis Bullosa Dystrophica clinical trials

Every programme with a company-led study here in the last two years, whatever its size: 6 programmes from 5 companies, 5 with this as their studies’ main aim; 4 with a live phase 3 study; 3 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 in phase 3 with the nearest primary completion, of 6 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

• Dec 2026 est.KB803 · Krystal Biotech, Inc. · Phase 3 main aimNCT07016750 A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa — primary endpoint: To evaluate the safety and tolerability of KB803. · 16 enrolled
• 15 Mar 2027 est.ENERGI-F703EB Cream · Energenesis Biomedical Co., Ltd. · Phase 2 named, not the main aimNCT07858422 A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa — primary endpoint: Incidence of Local Target Lesion Adverse Events · 24 enrolled
• Sep 2027 est.D-Fi · Castle Creek Biosciences, LLC. · Phase 3 main aimNCT06892639 Evaluation of D-Fi for the Treatment of Wounds Due to DEB — primary endpoint: The difference in Complete (100%) Wound Closure of the Target Wound Pair at either Week 22 (Visit 6), and Week 24 (Visit 7) or at Week 24 (Visit 7) and Week 26 (Visit 8) as assessed by a Blinded Assessor. · 32 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorised original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licences, line of therapy, academic comparators, sales.